Arjun Balar, MD, NYU Langone Health Perlmutter Cancer Center, New York City, NY, shares an update on the EV-201 trial (NCT03219333) investigating enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who have previously received PD-1/L-1 inhibitor treatment. Cohort 1 of the EV-210 trial led to accelerated approval of enfortumab vedotin in adult patients with locally advanced or metastatic urothelial cancer, who have previously received a PD-1/L-1 inhibitor and platinum-based chemotherapy. Cohort 2 investigated enfortumab vedotin in cisplatin-ineligible patients who have received a prior PD-1/L-1 inhibitor. 91 patients were enrolled in cohort 2. Cohort 2 reported an overall response rate (ORR) of 52% and a complete response rate of 20% among treated patients. The median duration of response was 10.9 months, the median progression-free survival (PFS) was 5.8 months, and the median overall survival (OS) was 14.7 months. 9% of patients discontinued enfortumab vedotin treatment due to progressive disease. This interview took place during the 2021 Genitourinary Cancers Symposium.
Dr Arjun Balar, MD, has received consultancy fees from Genentech, Incyte, Janssen, Merck, Pfizer, AstraZeneca/Medimmune, Nektar, Seattle Genetics and Immunomedics; has received fees for contracted research from Genentech, Merck, AstraZeneca/Medimmune, Nektar, Seattle Genetics and Immunomedics; has participated in speaking engagements for Genentech, Merck and AstraZeneca/Medimmune; has participated in steering committees with Merck and Nektar; and has equity and is a member of the scientific advisory board of EpiVax Oncology.